Edition:
United States

Consort Medical PLC (CSRT.L)

CSRT.L on London Stock Exchange

974.00GBp
11:39am EDT
Change (% chg)

34.00 (+3.62%)
Prev Close
940.00
Open
940.00
Day's High
990.00
Day's Low
932.00
Volume
22,022
Avg. Vol
23,400
52-wk High
1,294.00
52-wk Low
700.00

Latest Key Developments (Source: Significant Developments)

Consort Medical Says Dev610 FDA Approval For Mylan's Generic Advair
Thursday, 31 Jan 2019 02:01am EST 

Jan 31 (Reuters) - Consort Medical PLC ::DEV610: FDA APPROVAL FOR MYLAN'S GENERIC ADVAIR.FDA GRANTED ABBREVIATED NEW DRUG APPLICATION APPROVAL FOR MYLAN'S WIXELA INHUB.BOARD'S OUTLOOK FOR GROUP REMAINS UNCHANGED.  Full Article

Consort Medical HY Revenue 152.5 Mln Stg Vs 153.7 Mln Stg
Tuesday, 4 Dec 2018 02:01am EST 

Dec 4 (Reuters) - Consort Medical PLC ::HY CONSORT DELIVERED UNDERLYING EBIT GROWTH OF 2.5% WITH REVENUE BROADLY IN LINE WITH PRIOR YEAR.CLOSELY WITH CUSTOMERS ON BREXIT CONTINGENCY PLANS WHICH MAY RESULT IN A FURTHER INCREASE IN INVENTORY BALANCE BY YEAR END.HY REVENUE 152.5 MILLION STG VERSUS 153.7 MILLION STG.  Full Article

Opiant Pharma And Consort Medical PLC Announce Manufacturing Agreement
Monday, 10 Sep 2018 08:00am EDT 

Sept 10 (Reuters) - Consort Medical PLC ::OPIANT PHARMACEUTICALS, INC. AND CONSORT MEDICAL PLC ANNOUNCE MANUFACTURING AGREEMENT FOR OPNT003, INTRANASAL NALMEFENE, FOR TREATMENT OF OPIOID OVERDOSE.OPIANT PHARMACEUTICALS INC - AESICA & BESPAK WILL WORK WITH OPIANT TO PRODUCE A PRE-FILLED DELIVERY NASAL SPRAY WITH NALMEFENE.OPIANT PHARMACEUTICALS INC - AESICA WILL SUPPLY OPIANT WITH CLINICAL SAMPLES AND REGISTRATION BATCHES FOR PURPOSES OF PERFORMING CLINICAL STUDIES.OPIANT PHARMACEUTICALS INC - UPON APPROVAL BY U.S. FDA, AESICA AND BESPAK WILL MANUFACTURE AND SUPPLY COMMERCIAL DEVICE FOR OPIANT.OPIANT PHARMACEUTICALS INC - OPIANT INTENDS TO INITIATE A CONFIRMATORY PHARMACOKINETIC STUDY IN EARLY 2019.OPIANT PHARMACEUTICALS INC - OPIANT INTENDS TO PURSUE A 505(B)(2) DEVELOPMENT PATH FOR OPNT003.OPIANT PHARMACEUTICALS INC - OPIANT ANTICIPATES POTENTIAL TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020.OPIANT PHARMACEUTICALS INC - OPIANT RETAINS FULL COMMERCIAL RIGHTS TO OPNT-003.  Full Article

Consort Medical, Opiant To Develop Delivery Device For Opioid Overdose Treatment
Monday, 10 Sep 2018 02:00am EDT 

Sept 10 (Reuters) - Consort Medical PLC ::SIGNS DEVELOPMENT AGREEMENTS WITH OPIANT PHARMACEUTICALS.OPIANT WORKING WITH CO TO DEVELOP A DELIVERY DEVICE FOR OPNT003 FOR TREATMENT OF OPIOID OVERDOSE.CO, OPIANT INTEND TO DEVELOP A READY-TO-USE NASAL-DELIVERED VERSION OF NALMEFENE FOR REVERSAL OF OPIOID OVERDOSE.AFTER COMPLETION OF OPNT003 FORMULATION STUDIES, OPIANT INTENDS TO INITIATE CONFIRMATORY PHARMACOKINETIC STUDY IN 2019.BASED ON PREVIOUSLY OBTAINED FEEDBACK FROM FDA, OPIANT INTENDS TO PURSUE A 505(B)(2) DEVELOPMENT PATH FOR OPNT003.ANTICIPATES POTENTIAL TO SUBMIT A NEW DRUG APPLICATION FOR DRUG AND INTRANASAL DELIVERY DEVICE COMBINATION IN 2020.OPIANT RETAINS FULL COMMERCIAL RIGHTS TO OPNT-003.  Full Article

Schroders Cuts Stake In Consort Medical To Below 5 Pct From 9.508 Pct- Filing
Thursday, 23 Aug 2018 11:51am EDT 

Aug 23 (Reuters) - Consort Medical PLC ::SCHRODERS PLC CUTS STAKE IN CONSORT MEDICAL PLC TO BELOW 5 PERCENT FROM 9.508 PERCENT- FILING.  Full Article

Carclo Extends Pusu Deadline
Monday, 23 Jul 2018 02:03am EDT 

July 23 (Reuters) - Carclo PLC ::EXTENSION OF PUSU DEADLINE.CARCLO PLC, ON CONSORT MEDICAL PLC OFFER, SAYS PANEL GRANTED EXTENSION FOR PUSU TO 13 AUGUST 2018.  Full Article

Carclo Responds To Announcement From Consort Medical
Monday, 2 Jul 2018 08:07am EDT 

July 2 (Reuters) - Carclo Plc ::RESPONSE TO ANNOUNCEMENT FROM CONSORT MEDICAL.CONFIRMS THAT IT RECEIVED A HIGHLY PRELIMINARY INDICATIVE NON-BINDING ALL PAPER PROPOSAL FOR COMPANY FROM CONSORT.PROPOSAL VALUED EACH CARCLO SHARE AT 116 PENCE TO BE SATISFIED IN NEW CONSORT SHARES.BOARD WAS UNANIMOUS IN REJECTING THIS OPPORTUNISTIC APPROACH ON 01 JUNE 2018.  Full Article

Consort Medical Says Carclo's Board Rejected Co's Proposal
Monday, 2 Jul 2018 02:00am EDT 

July 2 (Reuters) - Consort Medical Plc ::NON-BINDING PROPOSAL FOR CARCLO PLC.PROPOSAL VALUED EACH SHARE IN CARCLO AT 116 PENCE PER SHARE.OFFER HAS AN IMPLIED AN EXCHANGE RATIO OF 0.0973 CONSORT SHARES FOR EACH CARCLO SHARE.BOARD OF CARCLO REJECTED PROPOSAL ON 1 JUNE 2018.BOARD OF CARCLO REJECTED FURTHER REQUESTS FROM CONSORT FOR A MEETING..BOARD OF CONSORT BELIEVES THAT PROPOSAL OFFERS SHAREHOLDERS IN CARCLO "AN ATTRACTIVE UPFRONT PREMIUM".BOARD OF CONSORT WILL CONTINUE TO EVALUATE CARCLO'S LED TECHNOLOGIES AND AEROSPACE BUSINESSES.  Full Article